Aortic valve replacement today: Outcomes, costs, and opportunities for improvement

The introduction of transcatheter aortic valve replacement (TAVR) just two decades ago has transformed the treatment of severe symptomatic aortic stenosis. TAVR has not only extended the option of aortic valve replacement to patients deemed ineligible for surgery, it has also demonstrated similar or better short- and intermediate-term clinical outcomes compared with surgical aortic valve replacement (SAVR) in patients at all levels of surgical risk. These benefits have been achieved with similar or lower costs compared with SAVR, at least in the first 1–2 years for intermediate- and low-risk patients. Longer-term data will further inform clinical and shared decision-making. In just over two decades, transcatheter aortic valve replacement has emerged as a frontline approach for appropriately selected patients with severe aortic stenosis. A growing body of evidence documents similar or better clinical outcomes and cost-effectiveness for transcatheter compared with surgical aortic valve replacement. Whether the mode is transcatheter or surgical, aortic valve replacement remains underutilized in patients with clear indications for intervention. •The TAVR patient population and the procedure itself have changed dramatically.•TAVR has extended aortic valve replacement to patients across all risk groups.•Clinical outcomes similar or better with TAVR vs surgery; overall costs lower.•Despite these advances, aortic valve replacement remains underutilized.